抗肿瘤坏死因子α难治性非感染性葡萄膜炎的生物制剂转换策略:系统综述与荟萃分析
该系统综述与荟萃分析纳入136项研究(129项病例报告/系列和7项比较研究),其中89项进入荟萃分析,评估抗TNFα难治性非感染性葡萄膜炎患者转换生物制剂后的应答率。总体汇总应答率为83%(95%CI 76%-90%),类别内转换应答率77%(95%CI 65%-87%)低于类别间转换的89%(95%CI 80%-96%),但差异未达统计学显著(P=0.0995);敏感性分析显示类别内71%对类别间85%,差异显著(P=0.044)。证据确定性评为低。
要点
- 抗TNFα难治性NIU转换生物制剂后总体汇总应答率为83%。
- 类别间转换应答率89%高于类别内转换的77%,但主分析差异未达显著。
- 敏感性分析显示类别间转换应答率显著高于类别内转换(P=0.044)。
核心结论
- 类别内和类别间转换策略均显示有效,类别间转换应答率更高,但证据确定性有限需谨慎解读。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、EMBASE和Cochrane Library至2025年1月5日,注册于PROSPERO(CRD420251071702)。
- 共纳入136项研究进行系统综述(129项病例报告/系列和7项比较研究),其中89项贡献于荟萃分析。
- 转换策略分为类别内(抗TNFα药物间转换)和类别间(从抗TNFα药物转换为不同类别生物制剂)进行比较。
- 使用JBI清单和Newcastle-Ottawa量表评估偏倚风险,采用GRADE方法评估主要结局证据确定性。
主要发现
- 转换后总体汇总应答率为83%(95%CI 76%-90%;I2=30.2%;466例患者)。
- 类别内转换汇总应答率为77%(95%CI 65%-87%;I2=36%),低于类别间转换的89%(95%CI 80%-96%;I2=18%),P=0.0995。
- 敏感性分析显示类别内转换汇总应答率为71%(95%CI 59%-82%;I2=54.5%),类别间转换为85%(95%CI 77%-93%;I2=32.8%),差异有统计学意义(P=0.044)。
- 使用JBI工具评估的77项研究中11项为高偏倚风险,其余至少为中等质量;比较研究中三分之一为中等偏倚风险,其余为低风险。
- 总体汇总应答率的证据确定性评为低。
关键数值与推荐
- 抗TNFα难治性非感染性葡萄膜炎患者转换生物制剂后总体汇总应答率83%(95%CI 76%-90%)。
- 类别内转换汇总应答率77%(95%CI 65%-87%),类别间转换89%(95%CI 80%-96%),主分析P=0.0995。
- 敏感性分析类别内转换71%(95%CI 59%-82%),类别间转换85%(95%CI 77%-93%),P=0.044。
临床怎么用
- 对于抗TNFα难治性非感染性葡萄膜炎,类别内和类别间生物制剂转换均可考虑作为治疗选择。
- 类别间转换可能提供更高应答率,但证据确定性低,临床决策需结合患者具体情况谨慎权衡。
局限性
- 纳入研究以病例报告/系列为主(129/136),比较研究仅7项,证据等级有限。
- 总体汇总应答率的证据确定性经GRADE评为低。
- 部分研究存在高偏倚风险(JBI评估77项中11项为高风险)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC: This study aimed to investigate switching strategies of biologics in noninfectious uveitis (NIU) refractory to anti-tumor necrosis factor alpha (TNFα) agents. CLINICAL RELEVANCE: Noninfectious uveitis often requires biologic therapy when conventional immunosuppression fails. Tumor necrosis factor alpha inhibitors, such as adalimumab and infliximab, are commonly used as first-line biologics, but up to one-third of patients experience inadequate responses. METHODS: We conducted a systematic review and meta-analysis to evaluate clinical outcomes following biologic switching in patients with NIU refractory to anti-TNFα therapy. This review was registered at PROSPERO (CRD420251071702). PubMed, EMBASE, and Cochrane Library were searched through January 5, 2025. Switching strategies were categorized as either intraclass (switching between anti-TNFα agents) or interclass (switching from an anti-TNFα agent to a different class biologic). Pooled response rates were compared between the two approaches. Risk of bias was assessed using the Joanna Briggs Institute (JBI) checklists for case reports/series and the Newcastle-Ottawa Scale for comparative studies. Certainty of evidence for primary outcome was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation approach. RESULTS: A total of 136 studies (129 case reports/series and 7 comparative studies) were included for systematic review, with 89 studies contributing to the meta-analysis. Using the JBI tool, 11 of 77 studies had high risk of bias, while the remainder were of at least fair quality. Among comparative studies, one-third had moderate risk of bias, while the rest were rated as low risk. The overall pooled response rate after switching was 83% (95% confidence interval [CI]: 76%-90%; I2 = 30.2%; 466 patients). Intraclass switching showed a pooled response rate of 77% (95% CI: 65%-87%; I2 = 36%), which was lower than that of interclass switching showing 89% (95% CI: 80%-96%; I2 = 18%, P = 0.0995). Sensitivity analyses showed a 71% (95% CI: 59%-82%, I2 = 54.5%) pooled response rate for intraclass switch and 85% (95% CI: 77%-93%, I2 = 32.8%) for interclass switch, revealing statistically significant difference (P = 0.044). The certainty of evidence was graded as low for the overall pooled response rate after switching. CONCLUSIONS: Both intraclass and interclass switching strategies appear effective, with interclass switching showing higher response rates; however, these findings warrant cautious interpretation given the limited certainty of evidence. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Chung YR, Rodríguez-Fernández CA, Song JH, et al. Biologic Switching Strategies for Anti-Tumor Necrosis Factor Alpha Refractory Noninfectious Uveitis: Systematic Review and Meta-Analysis of Clinical Approach. Ophthalmology. 2026. PMID: 42742496. doi:10.1016/j.ophtha.2026.07.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。